Sanifit to Participate at Upcoming Investor Conferences in November 2020
Palma, Spain and San Diego, USA, 2 November 2020 – Sanifit, a clinical-stage biopharmaceutical company focused on developing treatments for calcification disorders, today announced that Joan Perelló, Chief Executive Officer, and Adam Levy, Chief Financial Officer, will participate in the following virtual investor conferences in November:
Credit Suisse 29th Annual Healthcare Conference
Management will present an overview of the company and its programs and be available for one-on-one meetings with investors on 12 November 2020. The presentation will take place at 11:00 a.m. EST.
Jefferies Virtual London Healthcare Conference
Management will be available for one-on-one meetings with investors from 17-19 November 2020.
Piper Sandler 32nd Annual Healthcare Conference
Management will present an overview of the company and its programs and be available for one-on-one meetings with investors on 30 November 2020.
Sanifit is a clinical-stage biopharmaceutical company focused on treatments for vascular calcification disorders. The Company is a spin-off from the University of the Balearic Islands and has offices in Spain and the U.S. Sanifit’s lead asset, SNF472, has successfully completed a Phase 2 proof of concept study in calciphylaxis, and showed a significant reduction in progression of coronary calcification in a Phase 2b study among hemodialysis patients. A Phase 3 pivotal study in calciphylaxis is currently underway and the Company is also pursuing peripheral arterial disease in end-stage kidney disease patients as a second indication for SNF472. For more information, please visit www.sanifit.com.
Joan Perelló, CEO
Adam Levy, CFO
Consilium Strategic Communications
Amber Fennell, Chris Welsh, Sarah Wilson
+44 (0) 20 3709 5700